144 related articles for article (PubMed ID: 20179607)
1. Pharmacogenetic interactions between Angiotensin-converting enzyme insertion/deletion polymorphism and response to cibenzoline in patients with hypertrophic obstructive cardiomyopathy.
Ogimoto A; Okayama H; Nagai T; Ohtsuka T; Suzuki J; Inoue K; Nishimura K; Saito M; Shigematsu Y; Hamada M; Miki T; Higaki J
J Cardiovasc Pharmacol; 2010 May; 55(5):506-10. PubMed ID: 20179607
[TBL] [Abstract][Full Text] [Related]
2. Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy.
Hamada M; Shigematsu Y; Ikeda S; Hara Y; Okayama H; Kodama K; Ochi T; Hiwada K
Circulation; 1997 Sep; 96(5):1520-4. PubMed ID: 9315541
[TBL] [Abstract][Full Text] [Related]
3. Impact of chronic use of cibenzoline on left ventricular pressure gradient and left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy.
Hamada M; Ikeda S; Ohshima K; Nakamura M; Kubota N; Ogimoto A; Shigematsu Y
J Cardiol; 2016 Mar; 67(3):279-86. PubMed ID: 26116980
[TBL] [Abstract][Full Text] [Related]
4. Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy.
Sekine T; Daimon M; Hasegawa R; Teramoto K; Kawata T; Tanaka N; Takei Y; Takazawa K; Yoshida K; Komuro I
Heart Vessels; 2006 Nov; 21(6):350-5. PubMed ID: 17143709
[TBL] [Abstract][Full Text] [Related]
5. Antiarrhythmic drug cibenzoline attenuates left ventricular pressure gradient and improves transmitral Doppler flow pattern in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction.
Hamada M; Shigematsu Y; Inaba S; Aono J; Ikeda S; Watanabe K; Ogimoto A; Ohtsuka T; Hara Y; Higaki J
Circ J; 2005 Aug; 69(8):940-5. PubMed ID: 16041163
[TBL] [Abstract][Full Text] [Related]
6. Effect of cibenzoline, a class ia antiarrhythmic agent, on left ventricular diastolic function in hypertrophic cardiomyopathy.
Kondo I; Mizushige K; Nozaki S; Iwado Y; Masugata H; Kohno M; Matsuo H
Cardiovasc Drugs Ther; 2001 Sep; 15(5):459-65. PubMed ID: 11855665
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy: its relationship to transmitral Doppler flow profiles.
Hamada M; Aono J; Ikeda S; Watanabe K; Inaba S; Suzuki J; Ohtsuka T; Shigematsu Y
Circ J; 2007 Oct; 71(10):1540-4. PubMed ID: 17895548
[TBL] [Abstract][Full Text] [Related]
8. Effect of cibenzoline on regional left ventricular function in hypertrophic obstructive cardiomyopathy.
Kondo I; Mizushige K; Nozaki S; Hirao K; Iwado Y; Ohmori K; Matsuo H
Clin Cardiol; 2000 Sep; 23(9):689-96. PubMed ID: 11016020
[TBL] [Abstract][Full Text] [Related]
9. Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy.
Hamada M; Shigematsu Y; Hara Y; Suzuki M; Ohtsuka T; Hiasa G; Ogimoto A; Saeki H; Suzuki J; Hiwada K
Jpn Circ J; 2001 Jun; 65(6):531-8. PubMed ID: 11407736
[TBL] [Abstract][Full Text] [Related]
10. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
Kajimoto K; Imai T; Minami Y; Kasanuki H
Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829
[TBL] [Abstract][Full Text] [Related]
11. Mitral regurgitation disappearance after cibenzoline treatment in a patient with hypertrophic obstructive cardiomyopathy.
Inada K; Komukai K; Mori C; Nagasawa H; Shibata T; Mochizuki S
Intern Med; 2004 Jan; 43(1):55-8. PubMed ID: 14964580
[TBL] [Abstract][Full Text] [Related]
12. Effect of cibenzoline on biventricular pressure gradients in a pediatric patient with hypertrophic obstructive cardiomyopathy.
Ishikawa T; Iwashima S; Ohzeki T
Pediatr Cardiol; 2010 Jul; 31(5):707-10. PubMed ID: 20140606
[TBL] [Abstract][Full Text] [Related]
13. Reappearance of the left ventricular pressure gradient in a patient with hypertrophic obstructive cardiomyopathy.
Ochiumi Y; Ikeda S; Hamada M
Intern Med; 2015; 54(7):805-6. PubMed ID: 25832946
[TBL] [Abstract][Full Text] [Related]
14. Progression of left ventricular hypertrophy and the angiotensin-converting enzyme gene polymorphism in hypertrophic cardiomyopathy.
Doolan G; Nguyen L; Chung J; Ingles J; Semsarian C
Int J Cardiol; 2004 Aug; 96(2):157-63. PubMed ID: 15314809
[TBL] [Abstract][Full Text] [Related]
15. Impact of cibenzoline treatment on left ventricular remodelling and prognosis in hypertrophic obstructive cardiomyopathy.
Hamada M; Shigematsu Y; Ikeda S; Ohshima K; Ogimoto A
ESC Heart Fail; 2021 Dec; 8(6):4832-4842. PubMed ID: 34713615
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of cibenzoline for chest oppression and ventricular arrhythmia during effort and alcohol consumption in a patient with hypertrophic obstructive cardiomyopathy: a case report].
Sasayama T; Horimoto M; Takeda T; Takenaka T; Inoue H; Igarashi K; Akino M; Kikuchi K
J Cardiol; 2000 Jun; 35(6):445-50. PubMed ID: 10884982
[TBL] [Abstract][Full Text] [Related]
17. [The effect of polymorphisms of the angiotensin-converting enzyme and angiotensinogen genes on the phenotypic expression of Spanish patients with hypertrophic cardiomyopathy].
López-Haldón J; García-Lozano JR; Martínez Martínez A; Núñez-Roldán A; Burgos Cornejo J
Med Clin (Barc); 1999 Jul; 113(5):161-3. PubMed ID: 10480137
[TBL] [Abstract][Full Text] [Related]
18. [ACE gene polymorphism correlation (I/D) with the ventricular function in patients with ischemic and idiopathic dilated cardiomyopathy].
Avila-Vanzzini N; Espínola-Zavaleta N; Masso-Rojas F; Varela-López E; Casanova-Garcés JM; Kury-Alfaro J; Herrera-Bello H
Rev Invest Clin; 2006; 58(1):39-46. PubMed ID: 16789598
[TBL] [Abstract][Full Text] [Related]
19. The relationship between angiotensin converting enzyme gene I/D polymorphism and QT dispersion in patients with hypertrophic cardiomyopathy.
Kaya CT; Gurlek A; Altin T; Kilickap M; Karabulut HG; Turhan S; Ozcan O; Bokesoy I; Oral D; Erol C
J Renin Angiotensin Aldosterone Syst; 2010 Sep; 11(3):192-7. PubMed ID: 20478904
[TBL] [Abstract][Full Text] [Related]
20. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy.
Osterop AP; Kofflard MJ; Sandkuijl LA; ten Cate FJ; Krams R; Schalekamp MA; Danser AH
Hypertension; 1998 Nov; 32(5):825-30. PubMed ID: 9822439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
